Introduction
Activation of the coagulation system is an important manifestation of the systemic inflammatory response of the host to infection 1 . Several in vivo models have been used to dissect the molecular mechanisms that contribute to coagulation activation by bacteria and bacterial products, including intravenous injection of low dose lipopolysaccharide (LPS) into healthy humans 2 . Tissue factor, a glycoprotein expressed on endothelial cells and monocytes upon stimulation, plays an essential role in coagulation activation induced by LPS or bacteria in vivo, as demonstrated by abolishment of this response by inhibitors of tissue factor [3] [4] [5] [6] .
Mitogen-activated protein kinases (MAPKs) participate in intracellular signaling
cascades that mediate inflammatory responses to infectious and noninfectious stimuli 7, 8 .
Recent in vitro studies have implicated one of these kinases, p38 MAPK, in the regulation of tissue factor expression on monocytes 9 , endothelial cells 10, 11 , and smooth muscle cells 12 . The role of p38 MAPK in activation of coagulation in vivo is not known.
This prompted us to evaluate the effect of BIRB 796 BS, a specific and potent inhibitor of p38 MAPK 13 , on the procoagulant response during human endotoxemia.
only.
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Materials and Methods

Design
This study was a randomized, double-blind, placebo-controlled experiment performed simultaneously with a study examining the effect of BIRB 796 BS on LPS-induced cytokine release and neutrophil activation 14 
5
Von Willebrand Factor (vWF) (Dakopatts, Ävlsjö, Sweden), and soluble E-selectin (sEselectin) (Diaclone, Besancon Cedex, France); plasmin-2-antiplasmin complexes (PAPc) were determined by a radio immunoassay described elsewhere 15 .
Statistical analysis
All values are given as means ± SEM. Differences in response curves between the 3 treatment groups were tested by repeated measurements analysis of variance. A P-value < 0.05 was considered to represent a statistically significant difference.
Results and discussion
We recently demonstrated that BIRB 796 BS inhibited LPS-induced p38 MAPK activation in blood leukocytes of healthy humans in vivo, which was associated with a profound reduction in the release of cytokines and neutrophil activation 14 . In the present study we sought to determine the role of p38 MAPK in the activation of the hemostatic mechanism in vivo.
Intravenous injection of LPS was associated with activation of the coagulation system, as reflected by a rise in the plasma concentrations of the prothrombin fragment F1+2 (Figure 1 ). High dose, but not low dose, BIRB 796 BS inhibited LPS-induced coagulation activation, both delaying and diminishing the increase in plasma F1+2 concentrations (P < 0.05 vs placebo). The most likely explanation for the anticoagulant effect of BIRB 796 BS is inhibition of tissue factor expression. Indeed, tissue factor is essential for activation of the coagulation system in this model of low grade endotoxemia 3, 6 , and p38 MAPK inhibition markedly diminishes LPS-induced tissue factor expression by monocytic cells in vitro 9 . Moreover, p38 MAPK activation also mediates tissue factor expression by endothelial cells stimulated with thrombin or vascular endothelial growth factor, and by vascular smooth muscle cells stimulated with thrombin [10] [11] [12] . Furthermore, IL-6 is an important mediator of LPS-induced coagulation activation in vivo 16 , and BIRB 796 BS inhibited IL-6 release in a dose-dependent way 14 . Thus, it is conceivable that in the high dose BIRB 796 BS group, the reduction of IL-6 production had an additional inhibitory effect on the activation of the coagulation system.
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The high dose of BIRB 796 BS also modestly inhibited the release of PAI-1 (P < 0.05 vs placebo). Knowledge of the role of p38 MAPK in the production and release of fibrinolytic mediators is limited. The production of PAI-1 by bovine aortic endothelial cells exposed to hypoxia was not dependent on p38 MAPK 17 The effect of BIRB 769 BS on endothelial cell activation, as reflected by the plasma concentrations of sE-selectin and vWF [18] [19] [20] , was also investigated. LPS administration elicited profound increases in the plasma levels of sE-selectin and vWF. These increases were attenuated by high dose BIRB 796 BS (both P < 0.05 vs placebo; Figure 2 ). P38
MAPK may play a direct role in signaling inflammatory effects into the interior of the vascular endothelium 10, 11, 21 , including the expression of E-selectin on stimulated endothelial cells 22, 23 . In addition, the reduced TNF-levels in subjects treated with the p38 MAPK inhibitor 14 may also have played a role in the attenuated endothelial cell activation, considering that elimination of TNF-abolishes this response during only.
For 19 . Thus, a combination of direct effects of p38 MAPK inhibition on endothelial cells and the inhibition of TNF-release may explain the effect of BIRB 796
BS on the secretion of sE-selectin and vWF.
In this and our previous study 14 we documented dose-dependent effects of BIRB 796 BS on various inflammatory responses. Nonetheless, the effect of BIRB 796 BS on p38
MAPK phosphorylation already seemed maximal at the lower dose of the inhibitor 14 .
Importantly, since the phosphorylation assays were done on blood leukocytes, this finding does not exclude a dose-dependent effect of BIRB 796 BS on p38 MAPK activation on inflammatory cells in tissues. The specificity of BIRB 796 BS for p38
MAPK was carefully documented earlier 13 .
We here demonstrate a role for p38 MAPK in activation of coagulation, fibrinolysis and the vascular endothelium during human endotoxemia. These findings extend earlier observations of the inhibitory effect of p38 MAPK inhibitors such as BIRB 796 BS on activation of the cytokine network and neutrophils 14, 24 , and illustrate the broad role of this kinase in inflammation in vivo.
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